Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Xequel Bio.

    Client Virtual Booth

    XEQUEL BIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Xequel Bio
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    777 Taylor Street Suite 1140 Fort Worth, Texas 76102
    Telephone
    Telephone
    843.388.3276
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://xequel.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin™

    Details:

    Under the agreement, Societal CDMO will provide to support the ongoing clinical development of iNexin™, a patented new chemical entity based on company's aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.


    Lead Product(s): iNexin

    Therapeutic Area: Ophthalmology Product Name: iNexin

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Societal CDMO

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement May 08, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

    Details:

    In clinical and preclinical studies, iNexin demonstrated acceleration of corneal healing and restoration of the ocular surface. This study demonstrated that iNexin was safe and well-tolerated and early efficacy signals were observed at the doses tested.


    Lead Product(s): iNexin

    Therapeutic Area: Ophthalmology Product Name: iNexin

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 27, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search